SI-BONE (NASDAQ:SIBN) raises FY2021 sales outlook from $89.00 million-90.00 million to $89.80 million-90.10 million.
Relmada Therapeutics Priced Upsized 8.82M Share Public Offering of Common Stock @$17/Share
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share.
